Mirdametinib

Definition

An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.

NCIT:C52195 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as Gomekli, MEK Inhibitor PD0325901, MIRDAMETINIB, PD 901, PD-0325901 — per NCIT

Also identified as

ATC L01EE05 per RXNORM
NCIT NCIT:C52195 per NCIT
UNII 86K0J5AK6M per RXNORM

Indications

Disease	Relation	Source
Plexiform neurofibroma	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Nervous system	may treat a disease of this organ	DERIVED · CC BY 4.0
Peripheral nervous system	may treat a disease of this organ	DERIVED · CC BY 4.0

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.